Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00263614 · ClinicalTrials.gov registry record
Evaluation of Chronic HBV Patients w/Evidence of HBV Replication and Normal or Minimally Elevated Liver Transaminases.
A clinical trial of Chronic Hepatitis B, sponsored by Gilead Sciences.
- Completed
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT00263614 is a study of Chronic Hepatitis B that has completed, run by Gilead Sciences. The registered enrollment target is 100 participants, below the 287-participant average among 14 other Chronic Hepatitis B trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00263614, a study of Chronic Hepatitis B, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine whether HBeAg-positive and HBeAg-negative patients with HBV DNA greater than or less than 5 log10 and 4 log10 copies/mL, respectively, and with normal or minimally elevated liver transaminases have histological evidence of active liver disease.
Conditions Studied
Study Locations (1)
California
- Gilead Sciences, Inc. - Foster City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2005-12 |
| Est. Completion | 2007-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00263614
The ClinicalTrials.gov registry entry for NCT00263614 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 287-participant average among 14 other Chronic Hepatitis B trials with a reported enrollment target (65% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Hepatitis B appearing as the primary indexed condition, and to 0 interventions.
NCT00263614 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00263614 about?
NCT00263614 is a clinical study titled "Evaluation of Chronic HBV Patients w/Evidence of HBV Replication and Normal or Minimally Elevated Liver Transaminases.". To determine whether HBeAg-positive and HBeAg-negative patients with HBV DNA greater than or less than 5 log10 and 4 log10 copies/mL, respectively, and with normal or minimally elevated liver transaminases have histological evidence of active liver disease.
What is the current status of trial NCT00263614?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2005-12. Estimated completion is 2007-06.
What conditions does trial NCT00263614 study?
This clinical trial studies the following conditions: Chronic Hepatitis B.
Who is sponsoring clinical trial NCT00263614?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00263614 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Hepatitis B
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B
RECRUITING · Phase 2
-
Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B
RECRUITING · Phase 2
-
Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection
RECRUITING · Phase 2
-
TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B
RECRUITING · Phase 1
-
Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)
ACTIVE NOT RECRUITING · Phase 3
-
Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.